Bioaffinity Technologies, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by bioAffinity Technologies, Inc. (Nasdaq: BIAF) on January 10, 2025. The company is an emerging growth company incorporated in Delaware, with principal executive offices in San Antonio, Texas. The report primarily addresses a compensatory arrangement for the Chief Executive Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation adjustments rather than periodic financial performance.
Material Changes
On January 10, 2025, the Compensation Committee approved an amendment to the employment agreement of Maria Zannes, the Company's Chief Executive Officer. The key changes include:
- Base Salary Increase: The annual base salary was increased to $300,000.
- Retroactive Application: The salary increase is retroactive to November 1, 2024.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of specific risks and contingencies beyond the standard incorporation of the amendment text by reference. No unusual items were reported.
Investor Verification Checklist
- Verify the exact terms of the employment amendment in Exhibit 10.1.
- Confirm the impact of the retroactive salary adjustment on the company's cash burn rate for the period starting November 1, 2024.
- Review the company's most recent 10-Q or 10-K for current liquidity status to assess the ability to fund the increased compensation.